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Abstract
Purpose: Hydration and urinary alkalinization are essential for reducing renal dysfunction with high dose methotrexate
(HDMTX). This report presents an analysis of institutional methods used to achieve adequate urinary alkalinization and
output for patients receiving single agent HDMTX. Renal and metabolic parameters of tolerance were examined.
Methods: Medical records of adult patients receiving HDMTX during the calendar years of 2008–2009 were retrospectively
reviewed to determine the time to achieve urine pH> 7. Number of hospital days, bicarbonate dose, ordered hydration rate,
urine output, and urine pH were assessed. A survival analysis model was run for time to urine pH> 7 using preadmission oral
bicarbonate as a predictor variable and including a frailty term. Observational statistics were performed for other parameters.
Results: The analysis included 79 encounters for ten patients. Urine pH> 7 was achieved more rapidly in patients
receiving preadmission oral bicarbonate (P¼ 0.012). The number of patients receiving HDMTX on the same day as
admission was greater for those receiving preadmission oral bicarbonate (47%) in comparison to those who did not (2%),
and they spent less time in the hospital. A standard regimen for hydration and urinary alkalinization based on this project
is reported. The nature and frequency of adverse events were as expected for this treatment.
Conclusion: At our institution, the time to achieve urinary alkalinization was reduced for patients receiving preadmis-
sion oral bicarbonate which facilitated chemotherapy infusion on the same day as admission and decreased the number of
calendar days that patients stayed in the hospital.
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High-dose methotrexate (HDMTX) 3.5–8 g/m2 admin-
istered every 14 days is an integral part of therapy for
the treatment of primary central nervous system lym-
phoma (PCNSL).1,2 There is a risk of regimen-related
renal impairment with administration of HDMTX.3
The rate of nephrotoxicity attributed to administra-
tion of HDMTX 3–8 g/m2 ranges from 18 to 81% of
patients.4–7 Obstructive uropathy due to precipitation
of methotrexate and the metabolites 7-hydroxymetho-
trexate and 2,4-diamino-N10-methylpteroic acid
within the renal tubules is considered to be the insti-
gating event, which can yield tubular necrosis and
renal failure.3 Ancillary treatments administered
with HDMTX to improve drug solubility and lessen
renotubular drug exposure are essential for reducing
regimen-related renal dysfunction. Alkalinization of
the urine pH from 6 to 7 increases the solubility
of methotrexate and its metabolites by 5- to 8-fold.
In addition, administration of intravenous fluids at a
rate of 2.5–3.5 L/m2 per 24 h hastens the transit of
methotrexate and its metabolites through the renal
tubules.3
The logistics required for treatment delivery and
patient monitoring with administration of HDMTX
and ancillary interventions generally warrants hospi-
talization. Hospital stay duration is largely determined
by the time required for administration of ancillary
treatments. Events that can prolong hospitalization
include diagnostic testing to assess disease response,
central venous line placement for drug delivery, med-
ically significant regimen-related adverse events, or
unexpected acute illness. At our institution, the speci-
fic method used to provide ancillary hydration and
urinary alkalinization for HDMTX administration
is oncologist-specific. All of the oncologists initiate
intravenous hydration with 5% dextrose solution
containing sodium bicarbonate, 100 or 150 mEq/L,
to the hospitalized patients in order to attain a urine
pH exceeding 7 or 7.5 and urine output exceeding
100mL/h. Only one oncologist instructs his patients
to take oral sodium bicarbonate prior to their admis-
sion for single-agent HDMTX. He instructs the
patients to ingest oral sodium bicarbonate 1300mg
every 4 h beginning the morning of their scheduled
admission.
This report presents findings from a quality improve-
ment project done to analyze the methods used by
our medical oncologists for providing urinary alkalini-
zation and hydration to patients with PCNSL undergo-
ing treatment with single-agent HDMTXwith respect to
the time to achieve the target urine pH values and the
number of hospital days per treatment encounter. The
project also examined renal andmetabolic parameters of
patient tolerance.
Materials and methods
Clinical data
The methodology and findings of our institutional qual-
ity project were reviewed by the institutional review
board and designated as exempt from full board review
according to the Department of Health and Human
Services-defined criteria for research.
The project identified adult patients treated with
single-agent HDMTX for PCNSL during the calendar
years of 2008 and 2009 by way of an electronic medi-
cation use inquiry and from the records of the clinical
pharmacist for adult oncology. The patient’s electronic
medical records were reviewed to determine the amount
of oral and intravenous sodium bicarbonate adminis-
tered and the time to achieve urine pH> 7. The amount
of bicarbonate in each 650mg tablet was 7.6 mEq. In
addition, the ordered rate of hydration was tallied.
Reported values for urine pH and urine output were
monitored from the start of the methotrexate infusion
until the serum methotrexate level was <0.05 micromo-
lar or the patient was discharged, whichever occurred
first. Data for urine output was noted as volume
100mL/h on the first day of hydration and equal to
or less than 2400mL/24 h on subsequent days. The
occurrence of serum bicarbonate values exceeding 40
mEq/L was noted for each encounter. A serum bicar-
bonate value exceeding 40 mEq/L is designated as a
critical value by the institutional laboratory. Analysis
of urine pH not exceeding 7, serum bicarbonate >40
mEq/L, and urine output <2400mL/24 h (<100mL/h)
was documented in a plus or minus manner with
respect to whether or not the event occurred during
each patient encounter.
The method used for calculating the number of hos-
pital days was chosen to provide data that was mean-
ingful for our practitioners and staff, and cleanly
quantifiable for retrospective data analysis. The
number of hospital days for each interval examined
was counted in increments of whole days. As an exam-
ple, admission at 09:00 or 16:00 on the same day would
count as one hospital day for each case. The total
number of hospital days per encounter (hospitalization)
equals the day of admission and all days through and
including the day of discharge. The number of hospital
days from admission to start of methotrexate equals the
day of admission and all days through and including
the day of methotrexate administration. The number of
hospital days from the start of methotrexate to dis-
charge equals the day of methotrexate infusion and
all days through and including day of discharge.
The frequency and severity of acute kidney injury and
elevated serum creatinine values were evaluated using
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the National Cancer Institute Common Terminology
Criteria of Adverse Events, version 4.8
Statistical analysis
Using the statistical software R,9 a survival analysis
model was run for time to urine pH> 7 using oral
bicarbonate as a predictor variable and including a
frailty term. Cox proportional hazards model was not
used to implement survival analyses because our data
had multiple observations per individual, which vio-
lates the assumption of the Cox model that individuals
are independent of each other. To account for this
dependence between individuals the Weibull distribu-
tion (a parametric model) was utilized. The frailty
term, which accounts for the dependence between indi-
viduals, was insignificant with a p value of 0.220 and a
Chi-square test statistic of 7.82. The test statistic and p
value for the oral bicarbonate predictor were given as
6.26 and 0.012, respectively. At the a¼ 0.05 level, this
gives evidence that the effect of oral bicarbonate was
significant. Observational statistics were performed for
other parameters.
Results
A total of 79 encounters for 10 patients with PCNSL
undergoing treatment with single-agent HDMTX were
identified for the calendar years of 2008 and 2009
(Table 1). The HDMTX was administered on hospital
day 1 or 2 for most encounters (Figure 1). The mean
number of total hospital days and the mean number of
hospital days between admission and start of HDMTX
were shorter by 0.7 days and 0.6 days for the patients
receiving oral bicarbonate. However, the mean number
of hospital days from start of the HDMTX infusion to
patient discharge was similar between the two groups,
which implicate an event or events preceding HDMTX
administration as the factor/factors influencing length
of hospital stay (Table 2). Target urine pH was
achieved in less time for patients taking preadmission
oral bicarbonate ( p¼ 0.012; Table 2). The number of
patients receiving HDMTX on the same day as admis-
sion was greater for those receiving oral and intrave-
nous bicarbonate in comparison to those receiving
intravenous bicarbonate only (Figure 1). One patient
receiving intravenous bicarbonate only routinely
received a 50 mEq bolus prior to initiation of the con-
tinuous intravenous infusion of alkaline hydration.
Despite this intervention, his methotrexate was initiated
on the second hospital day for 11 of 13 encounters.
Chemotherapy administration on the other two
encounters was delayed beyond hospital day 2 due to
time needed for the initial diagnosis of PCNSL and
placement of a peripherally inserted central catheter.
Patients receiving only intravenous bicarbonate were
administered more parenteral fluid and a higher daily
dose of bicarbonate (Table 3). The mean amount of
bicarbonate ordered for administration over a 24 h
period and the mean rate of hydration during the
same time frame were 1.4-fold and approximately 1.7-
fold greater, respectively, for patients receiving
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Figure 1. Hospital day of methotrexate administration: oral
and intravenous bicarbonate (light grey); intravenous bicarbonate
only (dark grey).
Table 2. Mean (standard deviation) time to urine pH> 7 and
mean (standard deviation) number of hospital days per encounter
Bicarbonate administration
Parameter
Oral and
intravenous
Intravenous
only
Time to urine pH> 7 (hours) 5.4 (3.9),
p¼ 0.012
10.8 (8.2)
Total number of hospital days 6.4 (2.4) 7.1 (3.9)
Admission to start of
HDMTX (days)
1.8 (1.2) 2.4 (2.0)
Start of HDMTX to
discharge (days)
5.5 (1.7) 5.5 (2.9)
HDMTX: High-dose methotrexate.
Table 1. Patient encounters
Bicarbonate administration
Parameter
Oral and
intravenous
Intravenous
only
Number of encounters 36 43
Number of patients 4 6
Patient age/ages 68, 70, 74, 78 56, 58, 60, 60, 74, 75
Male:female (number) 1:3 3:3
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intravenous alkalinization only, in comparison to those
receiving oral and intravenous alkalinization. The rate
of one or more urine pH values dipping to less than 7
was similar between the two groups. However, the rate
of recorded urine output being less than 2400mL/24 h
on at least 1 day of therapy was noted more frequently
in patients receiving oral bicarbonate therapy. Three-
fold more encounters of patients receiving oral plus
intravenous bicarbonate had at least 1 day during
which the recorded urine output was less than
2400mL/24 h. All patients receiving oral bicarbonate
therapy experienced at least 1 day of recorded urine
output below 2400mL/24 h versus one third of patients
receiving only intravenous bicarbonate.
Serum bicarbonate values exceeding 40 mEq/L were
noted in 1.6-fold more encounters of patients receiving
intravenous bicarbonate only (Table 4). However,
all patients receiving oral plus intravenous bicar-
bonate experienced at least one serum bicarbonate
value exceeding 40 mEq/L versus two thirds of those
receiving only intravenous bicarbonate. Mild-to-mod-
erate acute kidney injury occurred in a similar number
of encounters in both patient groups (Table 4).
All patients in the oral bicarbonate group experienced
mild-to-moderate acute kidney injury versus two thirds
of those receiving only intravenous bicarbonate.
However, Grades 3 and 4 acute kidney injury occurred
in two of 43 encounters (5%) receiving only intrave-
nous alkalinization and no patients receiving oral plus
intravenous bicarbonate. One patient was a 60-year-old
female, who experienced a doubling of serum creatinine
the morning after her first dose of HDMTX that was
administered at 11:20 the preceding day. This patient
required hemodialysis to manage her acute renal
failure. The second case of severe acute kidney injury
occurred with the second dose of methotrexate admin-
istered to a 75-year-old male, whose admission serum
creatinine was the same as his baseline value for cycle
one of chemotherapy. This gentleman did experience
Grade 1 acute kidney injury and Grade 2 changes
in serum creatinine with cycle one of HDMTX. Urine
pH values were consistently >7 for both encounters
with Grades 3 and 4 acute kidney injury. The rate of
Grades 1–4 changes in serum creatinine were similar for
both groups, when analyzed by encounter and per
patient.
Table 4. Regimen related adverse events
Bicarbonate administration
Adverse event
Oral and intravenous Intravenous only
Per encounter Per patient Per encounter Per patient
N (%) N (%) N (%) N (%)
Serum bicarbonate >40 mEq/L 7 (19) 4 (100) 13 (30) 4 (67)
Acute kidney injury
Grades 1 and 2 9 (25) 4 (100) 9 (21) 4 (67)
Grades 3 and 4 0 2 (5) 2 (33)
Elevated serum creatinine
Grades 1 and 2 25 (69) 4 (100) 26 (60) 6 (100)
Grades 3 and 4 1 (3) 1 (25) 2 (5) 2 (33)
Table 3. Urinary alkalinization and urine output
Bicarbonate administration
Parameter Oral and intravenous Intravenous only
Amount of bicarbonate ordered; mean (standard deviation)
Intravenous bicarbonate per 24 h (mEq) 407 (96) 647 (154)
Oral and intravenous bicarbonate per 24 h (mEq) 477 (96) 647 (154)
Rate of hydration (mL/h) 125–150 200–250
Rate of hydration (L/m2/24 h) 1.4–2 2–3.5
Urine pH< 7 per encounter; N (%) 7 (19) 5 (12)
Urine output< 100mL/h per encounter; N (%) 13 (36) 5 (12)
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Discussion
High-dose methotrexate is included in various chemo-
therapy regimens for lymphomas, leukemias, and oste-
osarcoma.10–14 This analysis was limited to patients
receiving single-agent HDMTX for the treatment of
PCNSL, in order to examine a similar group of patients
receiving the same therapy without the confounding
influence of additional concurrent or recent chemother-
apy agent administrations. The nature and severity
of adverse events attributed to administration of
HDMTX and ancillary treatments were as expected
for this type of therapy. The frequency of acute
kidney injury was within the rate reported in the med-
ical literature (18–81% of patients).4–7 Episodes of
markedly elevated serum bicarbonate were handled
appropriately on a case-by-case basis, and there were
no clinical adverse events in our patients attributable to
systemic alkalosis. One key aspect of ancillary treat-
ments for reducing methotrexate-related renal impair-
ment is that the targeted amounts for urine pH and
output are readily measureable by standard clinical
monitoring. A particular regimen for hydration and
urinary alkalinization may offer cost and convenience
benefits; however, the critical element for reducing the
nephrotoxicity of treatment with HDMTX is provision
of adequate hydration and urinary alkalinization.3
The data was harvested retrospectively as part of an
institutional quality project. The initial intent of the
quality project was to ascertain whether patients trea-
ted with single-agent HDMTX at our medical center
consistently received adequate urinary alkalinization
and hydration for this therapy. Analysis of the retro-
spectively collected data identified the divergent meth-
ods for urinary alkalinization and the impact on
hospital stay. A limitation to this work is that the
data was harvested from an institutional quality project
instead of a prospectively controlled clinical study. The
manner in which hospital days were tallied does not
delineate differences that may have arisen from patient
arrival on the nursing unit in the morning versus late in
the afternoon. This is why statistical analysis was lim-
ited to the documented element of time from start of
ancillary hydration to measurement of urine pH> 7.
The time frame from initiation of alkaline hydration
to urine pH> 7 provides an objective measure directly
related to sodium bicarbonate administration, which
the time to administration of HDMTX is contingent
upon. Moreover, detailed analysis of concurrent medi-
cation therapy and comorbidities was not performed as
part of the quality project. Standard practice at our
medical center includes pharmacist evaluation of med-
ication therapy to identify and address any concurrent
medications that can alter the pharmacokinetics or
safety of HDMTX. Albeit this was not documented
for inclusion in the quality project and the institutional
review board exemption covering publication of this
material did not support extraction of additional data
from patient medical records.
One weakness of the methodology for this report is
that the self-administered dose of oral sodium bicar-
bonate was not quantified for each patient. This was
not feasible with retrospective chart review because the
amount of sodium bicarbonate taken prior to admis-
sion was not routinely noted in the patient’s medical
record. Moreover, for cases where this information was
documented, the validity of the data was limited by the
uncertain reliability of self-reporting. Another caveat to
the findings of this project is that the retrospective data
collection was based on a chronologic time interval so
not all encounters for all patients were included in the
analysis. A more stringent investigation would have
been provided by analysis of all encounters for all
patients. For most patients, the first hospitalization
for their PCNSL encompasses the greatest number of
hospital days because it entails admission for manage-
ment of symptomatology that culminates in the subse-
quent cancer diagnosis. All such first encounters were
captured for all patients included in this analysis.
The mean time to achieve urine pH> 7 was two-fold
longer for patients receiving only intravenous alkaline
hydration beginning at the time of admission in com-
parison to those beginning oral bicarbonate the day of
admission prior to their hospitalization (Table 2). It is
evident from examination of data in Tables 2 and 3 that
the cumulative and hourly amounts of prescribed bicar-
bonate (oral and intravenous) from the initiation of
intravenous hydration to the time of urine pH> 7
were approximately 2.7- and 1.4-fold greater for
patients receiving intravenous alkalinization only (291
mEq over 10.8 h) in comparison to those receiving
intravenous and oral bicarbonate (109 mEq over
5.5 h). So, in addition to the amount of bicarbonate
administered, the rate of intravenous hydration likely
impacted the time to urinary alkalinization. Data in
Tables 2 and 3 also demonstrate that the cumulative
volume and hourly rates of hydration from the initia-
tion of intravenous hydration to the time of urine
pH> 7 were approximately 3-fold greater and 1.4- to
1.8-fold greater for patients receiving intravenous alka-
linization only (2160–2700mL over 10.8 h; 83–146mL/
m2/h) in comparison to those receiving intravenous and
oral bicarbonate (688–825mL over 5.5 h; 60–83mL/m2/
h). Reduced fluid intake with oral bicarbonate self-
administration relative to intravenous infusion of alka-
line hydration may lead to more rapid equilibration of
serum bicarbonate concentration to a value exceeding
the renal threshold for this base and underlie the rela-
tively rapid urinary alkalinization noted with this
intervention.15 The dilutional effect of intravenous
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hydration may explain why administration of sodium
bicarbonate 50 mEq as an intravenous bolus immedi-
ately prior to initiation of the continuous alkaline infu-
sion did not facilitate HDMTX administration on the
day of hospital admission for a particular patient.
At our institution, the duration of hospitalization
was reduced for most patients receiving oral bicarbon-
ate prior to admission for single-agent HDMTX.
However, continuation of oral bicarbonate therapy
throughout the patient’s hospitalization did not pro-
vide an advantage to parenteral delivery of daily bicar-
bonate requirements. In addition, there are advantages
to consolidating bicarbonate administration into the
intravenous fluid. The systemic exposure to bicarbonate
is certain with intravenous administration; whereas,
oral administration of bicarbonate yields variable sys-
temic concentrations. Administration of sodium bicar-
bonate 1300mg orally every 4 h while awake
necessitates the ingestion of 8 to 10 650mg tablets
throughout the course of the day. Presumably, most
patients would be pleased to stop this regimen earlier
rather than later. Moreover, system workflow is
improved by truncating the duration of oral bicarbon-
ate therapy.
Conclusion
At our institution, the time to achieve urinary alkalini-
zation was reduced for patients receiving preadmission
oral bicarbonate in comparison to administration
of intravenous bicarbonate only beginning with the
patient’s arrival on the nursing unit. In addition, patients
receiving oral bicarbonate prior to admission were more
likely to receive HDMTX on the same day as admission
and spend fewer calendar days in the hospital.
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